AI Score
Our AI model analyzes fundamental, technical, and statistical indicators
to predict the probability of a bullish trend over the next three months.
We regularly update and refine our models to deliver the most reliable forecasts
for you.
Bullish Probability | Sentiment | Score |
---|---|---|
+80% | Strong Buy | 10 |
+75% | Buy | 9 |
+70% | Buy | 8 |
+60% | Buy | 7 |
+50% | Hold | 6 |
+45% | Hold | 5 |
+40% | Hold | 4 |
+35% | Sell | 3 |
+30% | Sell | 2 |
+20% | Strong Sell | 1 |
Bid | 0.11 |
Market Cap | 6.17M |
Revenue (ttm) | - |
Net Income (ttm) | - |
EPS (ttm) | -299.06 |
PE Ratio (ttm) | 0 |
Forward PE | n/a |
Analyst | Buy |
Ask | 0.11 |
Volume | 3,495,113 |
Avg. Volume (20D) | 25,015,377 |
Open | 0.11 |
Previous Close | 0.11 |
Day's Range | 0.10 - 0.11 |
52-Week Range | 0.10 - 41.00 |
Beta | undefined |
About CNSP
CNS Pharmaceuticals, Inc., a clinical pharmaceutical company, engages in the development of anti-cancer drug candidates for the treatment of brain and central nervous system tumors. The company's lead drug candidate is Berubicin, an anthracycline that is in Phase I and II clinical trials that is used for the treatment of glioblastoma multiforme. It has license agreements with Houston Pharmaceuticals, Inc. and The University of Texas M.D. Anderson...
Analyst Forecast
According to 1 analyst ratings, the average rating for CNSP stock is "Buy." The 12-month stock price forecast is $0.5, which is an increase of 365.55% from the latest price.